%0 Journal Article %T 3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy %A El Sanadi, Caroline E. %A Ji, Xinge %A Kattan, Michael W. %J Annals of Translational Medicine %D 2020 %B 2020 %9 %! 3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy %K %X %U https://atm.amegroups.org/article/view/55933 %V 8 %N 21 %P 1345 %@ 2305-5847